SANTA CLARA, Calif. & AUSTIN, Texas--(BUSINESS WIRE)--Affymetrix Inc. (NASDAQ: AFFX) and Luminex Corporation (NASDAQ: LMNX) today announced a distribution agreement under which eBioscience, a business ...

Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix (Nasdaq:AFFX) and Ariosa Diagnostics, Inc. today announced the signing of a multi-year supply agreement covering Affymetrix arrays and instruments to ...

Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...

Affymetrix said today it will collaborate with XRGenomics to develop next-generation diagnostic tests for age-related diseases. The alliance builds on an existing partnership between the companies, as ...

Unique and optimized solution provides highly sensitive and reproducible RNA amplification and labeling from archived FFPE samples for biomarker discovery and validation on industry-leading ...

SANTA CLARA, Calif. -- Affymetrix today announced that it has signed an agreement with Avesthagen Limited, a leading biotechnology company based in Bangalore, India. Under the terms of the agreement, ...

SANTA CLARA, Calif., Oct. 19, 2006 – Affymetrix Inc. (Nasdaq: AFFX) announced today that researchers at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona have used the ...

Thermo Fisher Scientific has reached a deal to buy genetic analysis expert Affymetrix for $1.3 billion. The $14.00-per-share purchase price is about 50% above Affymetrix’s share price after the stock ...

An English Court of Appeals decision in November held that Affymetrix (Santa Clara, CA) has a valid license to critical DNA microarray technology developed by Oxford Gene Technology (OGT; Oxford, UK).

Mindy Lee-Olsen, 408-731-5523 (Media)Vice President, Marketing ServicesorDoug Farrell, 408-731-5285 (Investors)Vice President, Investor Relations (NASDAQ:AFFX) announced today the availability of ...